Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04619563 | A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients | unknown | Phase 2 | 42 | Shandong Cancer Hospital and InstituteOTHER | 1 | Nov 18, 2020 | clinicaltrials |
| NCT04631146 | Efficacy and Safety of Camrelizumab in Real-World Study | unknown | — | 450 | Guangdong Association of Clinical TrialsOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT02977169 | To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer | unknown | Phase 2 | 300 | Shanghai Chest HospitalOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04620837 | Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy | unknown | Phase 2 | 25 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT03402048 | The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial(EPIC) | unknown | Phase 3 | 567 | University of Turin, ItalyOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT04612673 | A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC | unknown | Phase 2 | 33 | China Medical University, ChinaOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT04613804 | Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy | unknown | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 3, 2020 | clinicaltrials |
| NCT04102982 | Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer(MWA in NSCLC) | unknown | Phase 2 | 200 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 2, 2020 | clinicaltrials |
| NCT03288870 | Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)(DOMINUS) | unknown | Phase 2 / Phase 3 | 218 | BiocadINDUSTRY | 2 | Oct 29, 2020 | clinicaltrials |
| NCT04604470 | Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2(I-SABR2_PDA) | unknown | — | 126 | Maastricht UniversityOTHER | 0 | Oct 27, 2020 | clinicaltrials |
| NCT04575415 | Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study(BELLA) | unknown | — | 272 | Guangdong Association of Clinical TrialsOTHER | 1 | Oct 20, 2020 | clinicaltrials |
| NCT04592666 | Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer(APPEAL) | unknown | Phase 2 | 226 | Fudan UniversityOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03048500 | Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | unknown | Phase 2 | 17 | Northwestern UniversityOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT04553887 | Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial(AUTUMN) | unknown | Phase 2 | 53 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03481101 | WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC(WHENII) | unknown | N/A | 60 | Rigshospitalet, DenmarkOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT04560244 | A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment | unknown | Phase 2 | 15 | Shandong Cancer Hospital and InstituteOTHER | 0 | Sep 23, 2020 | clinicaltrials |
| NCT04554875 | Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules | unknown | — | 1,000 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 18, 2020 | clinicaltrials |
| NCT04553601 | Molecular Imaging Visualization of Tumor Heterogeneity in Non-small Cell Lung Cancer | unknown | N/A | 150 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT03502850 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 507 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT04398940 | A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 71 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 11, 2020 | clinicaltrials |
| NCT04544644 | A Study of Combination Therapy in NSCLC | unknown | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 0 | Sep 10, 2020 | clinicaltrials |
| NCT04506242 | Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer | unknown | Phase 2 | 74 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Sep 9, 2020 | clinicaltrials |
| NCT04535739 | PCI for Patients With ES-SCLC After RCT:a Prospective Randomized Study | unknown | Phase 3 | 414 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT04416035 | A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC(NSCLC) | unknown | Phase 3 | 608 | Zhejiang Teruisi Pharmaceutical Inc.INDUSTRY | 1 | Aug 31, 2020 | clinicaltrials |
| NCT04530097 | Radiofrequency Ablation Combined With Melatonin in the Treatment of Stage IA NSCLC | unknown | N/A | 260 | Shanghai 10th People's HospitalOTHER | 1 | Aug 28, 2020 | clinicaltrials |
| NCT04530708 | Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLC(MARS) | unknown | N/A | 162 | Swedish Lung Cancer Study GroupNETWORK | 1 | Aug 28, 2020 | clinicaltrials |
| NCT03598517 | High Dose Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer | unknown | N/A | 50 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 25, 2020 | clinicaltrials |
| NCT04524299 | Study of Radiotherapy Combined With Albumin Bound Paclitaxel and Nedaplatin for Locally Advanced NSCLC | unknown | Phase 2 | 160 | Sun Yat-sen UniversityOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT04517019 | Randomised Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Radiotherapy(OnkoFit II) | unknown | N/A | 201 | University Hospital TuebingenOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT04136470 | BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics | unknown | — | 130 | ArdigenINDUSTRY | 1 | Aug 10, 2020 | clinicaltrials |
| NCT04501029 | A Study of Gimatecan (ST1481) in Small Cell Lung Cancer | unknown | Phase 2 | 70 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Aug 6, 2020 | clinicaltrials |
| NCT04500704 | Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC(ACROSS1) | unknown | Phase 3 | 166 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT04500717 | Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation(ACROSS2) | unknown | Phase 3 | 460 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT03267654 | Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance | unknown | Phase 2 | 100 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 3, 2020 | clinicaltrials |
| NCT04492969 | Prospective Observation of Failure Patterns in NSCLC Treated With ICIs | unknown | — | 320 | Fudan UniversityOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03998085 | Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC | unknown | N/A | 40 | The First Hospital of Jilin UniversityOTHER | 1 | Jul 30, 2020 | clinicaltrials |
| NCT04489862 | αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors | unknown | Early Phase 1 | 10 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT04487093 | Clinical Study of Neoantigen Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung Cancer | unknown | Phase 1 | 20 | First Hospital of Shijiazhuang CityOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT03532698 | Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC) | unknown | — | 100 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Jul 23, 2020 | clinicaltrials |
| NCT03758677 | Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation | unknown | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 1 | Jul 23, 2020 | clinicaltrials |
| NCT04482829 | TCM in the Treatment of Lung Adenocarcinoma | unknown | N/A | 144 | Henan University of Traditional Chinese MedicineOTHER | 0 | Jul 23, 2020 | clinicaltrials |
| NCT03734913 | A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 65 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT03923777 | Active Surveillance in Early Lung Cancer(ACTION-Lung) | unknown | N/A | 26 | University of Vermont Medical CenterOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT04470076 | Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation(Neoafa) | unknown | Phase 2 | 30 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Jul 14, 2020 | clinicaltrials |
| NCT03389087 | Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer | unknown | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 10, 2020 | clinicaltrials |
| NCT04461652 | The Effect of a Combined Drainage Strategy in Uniportal Upper Lung Lobectomy | unknown | N/A | 400 | Tongji UniversityOTHER | 1 | Jul 10, 2020 | clinicaltrials |
| NCT03848611 | CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). | unknown | Phase 2 | 20 | AnewPharmaINDUSTRY | 1 | Jul 9, 2020 | clinicaltrials |
| NCT03904719 | CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC) | unknown | Phase 2 | 30 | AnewPharmaINDUSTRY | 1 | Jul 9, 2020 | clinicaltrials |
| NCT04273815 | A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets | unknown | Phase 1 / Phase 2 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 8, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Nov 18, 2020source: clinicaltrials